Simplifying the Generic Drug Application Process Act
Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.
Simplifying the Generic Drug Application Process Act
This bill removes a requirement for a generic drug maker to, in some instances, petition the Food and Drug Administration (FDA) before seeking market approval for a generic drug.
Currently, if an applicant wishes to submit an abbreviated application (i.e., the type of application typically used to get market approval for a generic drug) for a drug that has a different dosage form or strength from an already-approved drug, the applicant must first petition the FDA for permission to submit the application. Under this bill, an applicant is no longer required to petition the FDA for permission in these instances.
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
- Introduced in Senate Formatted Text PDF Formatted XML
Cite this page
U.S. Congress. (2026). S. 1462: Simplifying the Generic Drug Application Process Act. 117th Congress. Open America. https://openamerica.io/bill/117-S-1462/
"S. 1462: Simplifying the Generic Drug Application Process Act." 117th Congress, 2026, Open America, https://openamerica.io/bill/117-S-1462/.
S. 1462, 117th Cong. (2026), https://openamerica.io/bill/117-S-1462/.
[S. 1462: Simplifying the Generic Drug Application Process Act](https://openamerica.io/bill/117-S-1462/)